GlassScriptPhysician profile
Gabriela Cobos
NPI 1235558925
$342,718.55
in general payments reported to CMS, 2019-2025
16 companies · $123K in 2025
The $123K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $99.99 · 2022: $1,180 · 2023: $83K · 2024: $135K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Consulting Fee: $84K · Travel and Lodging: $35K · Food and Beverage: $13K · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,283.50 |
| Consulting Fee | $83,992.21 |
| Travel and Lodging | $34,870.21 |
| Food and Beverage | $12,748.75 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $160,008.97 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $57,926.05 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $48,917.00 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $31,178.32 | 2023-2025 | Dupixent |
| Genzyme Corporation | $15,790.56 | 2023-2025 | |
| Abbvie INC. | $13,174.53 | 2019-2024 | Skyrizi, Rinvoq |
| Incyte Corporation | $6,883.37 | 2023-2024 | |
| Ucb, INC. | $4,315.35 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $2,151.59 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $1,901.31 | 2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $148.23 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $131.69 | 2023 | |
| Johnson & Johnson Health Care Systems INC. | $93.30 | 2025 | Tremfya |
| Janssen Research & Development, LLC | $59.11 | 2024 | |
| Amgen INC. | $23.78 | 2024 | Otezla |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $15.39 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriela Cobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.